Physician profile
Srinivas Duvvuri
NPI 1841237526
$5,539.11
in general payments reported to CMS, 2019-2025
21 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.10 · 2020: $68.17 · 2021: $676 · 2022: $3,128 · 2023: $574 · 2024: $586 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,361.90 | 2020-2022 | |
| Abbott Laboratories | $1,812.46 | 2021-2025 | Mitraclip, Dragonfly Opstar, Navitor |
| Philips North America LLC | $150.20 | 2022 | |
| Abiomed | $142.81 | 2021-2022 | |
| Medtronic, INC. | $142.05 | 2022-2025 | Symplicity G3, Onyx Frontier |
| Amgen INC. | $125.00 | 2025 | Repatha |
| Esperion Therapeutics, INC. | $124.76 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $120.42 | 2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $93.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $86.07 | 2019-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $69.09 | 2024 | Arcalyst |
| Boston Scientific Corporation | $58.69 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2020 | |
| Chiesi USA, INC. | $47.00 | 2024-2025 | Kengreal |
| Kestra Medical Technology Services, INC. | $38.55 | 2023 | Assure Wcd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.82 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Octapharma USA, INC. | $21.04 | 2025 | Fibryga |
| Medtronic Vascular, INC. | $20.35 | 2019 | |
| Scpharmaceuticals INC. | $19.81 | 2025 | |
| Pfizer INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Duvvuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.